Go Pro
→ Your book is inside (From Profits Run) (Ad)tc pixel Free MBAI Stock Alerts

Check-Cap (MBAI) Competitors

Check-Cap logo
$8.72 -0.11 (-1.25%)
Closing price 04:00 PM Eastern
Extended Trading
$8.60 -0.13 (-1.43%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

MBAI vs. QTEX, IINN, ELUT, ARAY, and TELA

Should you buy Check-Cap stock or one of its competitors? Check-Cap's main competitors and comparable companies include Inspira Technologies OXY B.H.N. (QTEX), Inspira Technologies OXY B.H.N. (IINN), Elutia (ELUT), Accuray (ARAY), and TELA Bio (TELA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Check-Cap compare to Inspira Technologies OXY B.H.N.?

Check-Cap (NASDAQ:MBAI) and Inspira Technologies OXY B.H.N. (NASDAQ:QTEX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

1.1% of Check-Cap shares are held by institutional investors. Comparatively, 12.7% of Inspira Technologies OXY B.H.N. shares are held by institutional investors. 0.5% of Check-Cap shares are held by company insiders. Comparatively, 29.4% of Inspira Technologies OXY B.H.N. shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Check-CapN/A N/A N/A
Inspira Technologies OXY B.H.N. N/A N/A N/A

In the previous week, Check-Cap had 2 more articles in the media than Inspira Technologies OXY B.H.N.. MarketBeat recorded 5 mentions for Check-Cap and 3 mentions for Inspira Technologies OXY B.H.N.. Inspira Technologies OXY B.H.N.'s average media sentiment score of 0.63 beat Check-Cap's score of 0.34 indicating that Inspira Technologies OXY B.H.N. is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Check-Cap
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Inspira Technologies OXY B.H.N.
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Check-Cap has higher earnings, but lower revenue than Inspira Technologies OXY B.H.N..

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Check-CapN/AN/A$4.14M-$2.01N/A
Inspira Technologies OXY B.H.N.$290K121.47-$13.22MN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Check-Cap
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Inspira Technologies OXY B.H.N.
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Check-Cap has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, Inspira Technologies OXY B.H.N. has a beta of 4.24, meaning that its share price is 324% more volatile than the broader market.

Summary

Inspira Technologies OXY B.H.N. beats Check-Cap on 5 of the 7 factors compared between the two stocks.

How does Check-Cap compare to Inspira Technologies OXY B.H.N.?

Check-Cap (NASDAQ:MBAI) and Inspira Technologies OXY B.H.N. (NASDAQ:IINN) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Company Net Margins Return on Equity Return on Assets
Check-CapN/A N/A N/A
Inspira Technologies OXY B.H.N. N/A N/A N/A

In the previous week, Check-Cap had 5 more articles in the media than Inspira Technologies OXY B.H.N.. MarketBeat recorded 5 mentions for Check-Cap and 0 mentions for Inspira Technologies OXY B.H.N.. Check-Cap's average media sentiment score of 0.34 beat Inspira Technologies OXY B.H.N.'s score of 0.00 indicating that Check-Cap is being referred to more favorably in the media.

Company Overall Sentiment
Check-Cap Neutral
Inspira Technologies OXY B.H.N. Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Check-Cap
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Inspira Technologies OXY B.H.N.
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

1.1% of Check-Cap shares are held by institutional investors. Comparatively, 12.7% of Inspira Technologies OXY B.H.N. shares are held by institutional investors. 0.5% of Check-Cap shares are held by insiders. Comparatively, 29.4% of Inspira Technologies OXY B.H.N. shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Check-Cap has higher earnings, but lower revenue than Inspira Technologies OXY B.H.N..

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Check-CapN/AN/A$4.14M-$2.01N/A
Inspira Technologies OXY B.H.N.$289K124.39-$13.22MN/AN/A

Check-Cap has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Inspira Technologies OXY B.H.N. has a beta of 2.16, indicating that its share price is 116% more volatile than the broader market.

Summary

Inspira Technologies OXY B.H.N. beats Check-Cap on 4 of the 7 factors compared between the two stocks.

How does Check-Cap compare to Elutia?

Check-Cap (NASDAQ:MBAI) and Elutia (NASDAQ:ELUT) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

Elutia has higher revenue and earnings than Check-Cap. Check-Cap is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Check-CapN/AN/A$4.14M-$2.01N/A
Elutia$12.29M3.28$53.38M$0.950.99

Check-Cap has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, Elutia has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

Elutia has a consensus target price of $6.00, suggesting a potential upside of 537.62%. Given Elutia's stronger consensus rating and higher probable upside, analysts clearly believe Elutia is more favorable than Check-Cap.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Check-Cap
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Elutia
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

1.1% of Check-Cap shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 0.5% of Check-Cap shares are held by insiders. Comparatively, 17.8% of Elutia shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Elutia had 2 more articles in the media than Check-Cap. MarketBeat recorded 7 mentions for Elutia and 5 mentions for Check-Cap. Check-Cap's average media sentiment score of 0.34 beat Elutia's score of 0.08 indicating that Check-Cap is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Check-Cap
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Elutia
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Elutia has a net margin of 426.93% compared to Check-Cap's net margin of 0.00%. Check-Cap's return on equity of 0.00% beat Elutia's return on equity.

Company Net Margins Return on Equity Return on Assets
Check-CapN/A N/A N/A
Elutia 426.93%-1,071.47%-45.79%

Summary

Elutia beats Check-Cap on 12 of the 15 factors compared between the two stocks.

How does Check-Cap compare to Accuray?

Accuray (NASDAQ:ARAY) and Check-Cap (NASDAQ:MBAI) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Accuray has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market. Comparatively, Check-Cap has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

Check-Cap has a net margin of 0.00% compared to Accuray's net margin of -10.76%. Check-Cap's return on equity of 0.00% beat Accuray's return on equity.

Company Net Margins Return on Equity Return on Assets
Accuray-10.76% -79.43% -10.38%
Check-Cap N/A N/A N/A

Accuray currently has a consensus price target of $2.00, suggesting a potential upside of 618.91%. Given Accuray's stronger consensus rating and higher possible upside, equities research analysts clearly believe Accuray is more favorable than Check-Cap.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Accuray
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Check-Cap
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Check-Cap has lower revenue, but higher earnings than Accuray. Check-Cap is trading at a lower price-to-earnings ratio than Accuray, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Accuray$458.51M0.07-$1.59M-$0.37N/A
Check-CapN/AN/A$4.14M-$2.01N/A

64.1% of Accuray shares are held by institutional investors. Comparatively, 1.1% of Check-Cap shares are held by institutional investors. 4.4% of Accuray shares are held by company insiders. Comparatively, 0.5% of Check-Cap shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Check-Cap had 3 more articles in the media than Accuray. MarketBeat recorded 5 mentions for Check-Cap and 2 mentions for Accuray. Accuray's average media sentiment score of 0.94 beat Check-Cap's score of 0.34 indicating that Accuray is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Accuray
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Check-Cap
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Accuray beats Check-Cap on 9 of the 14 factors compared between the two stocks.

How does Check-Cap compare to TELA Bio?

Check-Cap (NASDAQ:MBAI) and TELA Bio (NASDAQ:TELA) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

TELA Bio has a consensus price target of $2.20, indicating a potential upside of 241.46%. Given TELA Bio's stronger consensus rating and higher probable upside, analysts plainly believe TELA Bio is more favorable than Check-Cap.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Check-Cap
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
TELA Bio
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Check-Cap has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, TELA Bio has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market.

Check-Cap has higher earnings, but lower revenue than TELA Bio. Check-Cap is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Check-CapN/AN/A$4.14M-$2.01N/A
TELA Bio$80.28M0.36-$38.83M-$0.77N/A

1.1% of Check-Cap shares are held by institutional investors. Comparatively, 94.4% of TELA Bio shares are held by institutional investors. 0.5% of Check-Cap shares are held by insiders. Comparatively, 5.1% of TELA Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, TELA Bio had 2 more articles in the media than Check-Cap. MarketBeat recorded 7 mentions for TELA Bio and 5 mentions for Check-Cap. Check-Cap's average media sentiment score of 0.34 beat TELA Bio's score of -0.26 indicating that Check-Cap is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Check-Cap
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
TELA Bio
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Check-Cap has a net margin of 0.00% compared to TELA Bio's net margin of -51.53%. Check-Cap's return on equity of 0.00% beat TELA Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Check-CapN/A N/A N/A
TELA Bio -51.53%-4,549.79%-59.39%

Summary

TELA Bio beats Check-Cap on 10 of the 15 factors compared between the two stocks.

Get Check-Cap News Delivered to You Automatically

Sign up to receive the latest news and ratings for MBAI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MBAI vs. The Competition

Export
MetricCheck-CapHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$5.95B$7.06B$13.10B
Dividend YieldN/A1.76%2.57%10.45%
P/E Ratio-4.3426.22269.0625.28
Price / SalesN/A63.09602.4391.76
Price / CashN/A33.9270.4850.90
Price / Book2.646.1012.916.24
Net Income$4.14M$148.67M$3.45B$347.60M
7 Day Performance-11.65%1.84%1.12%1.07%
1 Month Performance10.24%4.56%1.79%1.03%
1 Year PerformanceN/A8.67%67.69%20.77%

Check-Cap Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MBAI
Check-Cap
0.3156 of 5 stars		$8.72
-1.2%		N/AN/A$0.00N/AN/A80
QTEX
Inspira Technologies OXY B.H.N.
0.2367 of 5 stars		$1.01
+1.4%		N/AN/A$36.31M$290KN/A20
IINN
Inspira Technologies OXY B.H.N.
N/A$1.00
-4.2%		N/A-24.1%$35.80M$289KN/A20
ELUT
Elutia
2.5156 of 5 stars		$0.82
+2.1%		$6.00
+633.5%		-60.2%$34.99M$12.29M0.95180
ARAY
Accuray
2.0692 of 5 stars		$0.28
-3.3%		$2.00
+614.3%		-81.5%$33.31M$458.51MN/A1,040

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:MBAI) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
AI insiders stockpile guns, gold & gas masks
Keith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...
TradeSmith | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
The Shocking Discovery Investigators Found Hidden Inside America's Port Cranes
U.S. investigators found unexplained cellular modems inside cranes made by a Chinese state-owned company that ...
Altimetry | Sponsoredtc pixel
How a rare metal shortage sent gains up 2512 percent
In 2010, a rare earth metal called dysprosium surged 2,512 percent in two and a half years after China cut exp...
Awesomely | Sponsoredtc pixel